PolyNovo Finalises Trial Report and Targets PMA Submission Before End of 2026
Clinical study milestone reached as PolyNovo targets PMA submission before end of 2026
PolyNovo Limited (ASX: PNV) has finalised the Clinical Study Report (CSR) for its U.S. pivotal randomised controlled trial (RCT) of NovoSorb® BTM, clearing a significant step toward its Premarket Approval (PMA) submission. Following updated FDA guidance that came into effect in February 2026, the company has proactively revised its submission plan, with the PMA application now expected before the end of calendar 2026.
Importantly, the adjusted timeline carries no material impact on current revenue, sales, or clinical use of NovoSorb® products. The revision reflects a quality-first approach aimed at producing a stronger, more review-ready submission package.
When big ASX news breaks, our subscribers know first
What’s changed — and why it strengthens PolyNovo’s position
Updated FDA guidance triggers proactive submission plan review
In February 2026, new FDA guidance relating to quality management system (QMS) information in PMA submissions came into effect. In response, PolyNovo undertook a comprehensive review of its submission plan, including the scope and sequencing of manufacturing and validation activities.
Certain activities originally planned post-submission will now be included upfront. This refinement is designed to strengthen the overall submission package, enhance inspection readiness, and align with evolving FDA expectations and PolyNovo’s own quality standards.
18-month follow-up data now included in submission package
The revised timeline also creates an opportunity to incorporate 18-month patient follow-up data into the final submission package. Notably, the 18-month follow-up data is a prerequisite for the granting of the PMA, meaning the associated FDA review timeline remains unchanged.
The recent appointment of Allison Myers as Chief Quality & Regulatory Affairs Officer further reinforces the company’s quality-focused approach, with the team prioritising the completion, validation, and documentation of key manufacturing and supplier processes.
Key changes to the submission plan include:
- CSR finalised based on 12-month follow-up data
- Updated FDA QMS guidance (effective February 2026) prompted plan review
- Select post-submission activities moved into the submission package
- 18-month follow-up data to be included in the final submission
- PMA submission expected before end of calendar 2026
- No impact on current revenue, sales, or clinical use
CEO Bruce Peatey
“We are pleased to have reached this important milestone with the completion of the Clinical Study Report and acknowledge the significant effort of our clinical, quality and operational teams in getting us here. We have taken a disciplined approach to ensure that every element of our PMA submission meets both current FDA expectations and our own quality standards. While this has resulted in an adjustment to timing, we believe it strengthens our submission and positions PolyNovo for long-term success in the U.S. Importantly, this has no impact on our existing commercial operations. Demand for NovoSorb® remains strong, and we continue to support clinicians and patients while progressing toward PMA submission.”
What is a PMA — and why does U.S. approval matter for investors?
A Premarket Approval (PMA) is the FDA’s most stringent regulatory pathway for medical devices. It is required for high-risk or novel products that cannot demonstrate equivalence to a previously cleared device. By contrast, a 510(k) clearance applies to devices that are substantially similar to an already-approved product and involves a less rigorous review process.
For PolyNovo, securing a PMA would unlock an on-label indication for NovoSorb® BTM specifically for full thickness burns in the United States. The U.S. is the world’s largest medical device market, making this regulatory approval a material commercial milestone for the company.
The clinical programme supporting this submission has been funded by the Biomedical Advanced Research and Development Authority (BARDA), a U.S. government agency that supports the development of medical countermeasures. BARDA’s involvement lends both credibility and financial backing to the pivotal RCT.
| Regulatory Term | What it means | Why it matters for PNV |
|---|---|---|
| PMA (Premarket Approval) | FDA’s most stringent device approval pathway | Required for NovoSorb® BTM’s on-label U.S. burns indication |
| CSR (Clinical Study Report) | Summary of trial findings used to support the PMA | Now finalised — clears the path to submission |
| QMS (Quality Management System) | Quality controls governing manufacturing processes | Updated FDA guidance prompted a revised submission plan |
The next major ASX story will hit our subscribers first
Submission runway intact — commercial momentum continues
Existing NovoSorb® product sales and clinical use continue unaffected under current approvals, with management confirming that demand remains strong. The PMA submission, expected before the end of calendar 2026, represents the next significant de-risking catalyst for PolyNovo’s U.S. commercial strategy. A successful PMA would enable on-label promotion of NovoSorb® BTM for full thickness burns in the U.S., representing a meaningful expansion of the company’s addressable market in the world’s largest medical device economy.
PolyNovo is an ASX-listed medical technology company headquartered in Melbourne, with international operations across the United States, United Kingdom, India, Hong Kong, Singapore, and several distributor-supported markets. The company’s proprietary NovoSorb® polymer platform underpins its wound care portfolio, with an established track record of revenue growth, profitability, and market leadership across multiple geographies. The PMA submission remains the next key milestone on the company’s path to broader U.S. market access.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors staying ahead of the market on medical technology and beyond. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.